CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
ALT-711drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00043836
NCT00043836Phase 2Completed
CompareCT.gov

A Pilot Study Of ALT-711 In Elderly Patients With Isolated Diastolic Heart Failure: The DIAMOND Study

Synvista Therapeutics, Inc·interventional·Posted Aug 15, 2002·Updated Sep 2, 2009

In Brief

A Phase 2 clinical trial evaluating ALT-711 for Heart Failure, Congestive and 2 related conditions. Completed, across 2 sites.

Detailed Summary

The purpose of this study is to test the hypothesis that treatment with oral ALT-711 twice daily for 16 weeks will improve aortic distensibility, exercise tolerance, and quality of life in elderly patients with isolated diastolic heart failure (DHF), and that the improvements in exercise tolerance will correlate with the improvements in aortic distensibility.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Congestive, Dyspnea, Pulmonary Edema
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2002
Enrollment StartJul 1, 2002
Primary CompletionFeb 1, 2003
Study CompletionOct 1, 2005
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 23.9 years ago

Interventions

ALT-711drug